13th Annual Health Care Supply Chain Summit

13th Annual Health Care Supply Chain Summit January 28-29, 2019 | New Orleans, LA Join senior supply chain executives from top hospitals as they share strategies to improve patient outcomes by optimizing and benchmarking supply chain operations. Key Themes in World Congress’ 13th Annual Health Care Supply Chain Summit 2019 include: Cost, quality and outcomes Clinical integration and physician alignment Supplier relationships Sustainability and standardization Strategic planning Value analysis and strategic sourcing Data, analytics, and technology Talent acquisition, supply chain leaderships, and professional development Logistics and distribution Engage in strategic discussions regarding next frontier supply chain operations with leaders from: … Continue reading 13th Annual Health Care Supply Chain Summit

Enhancing Care For and Management of Hepatitis C Patients

Today’s guest post comes from Lily Duong, Chief Clinical Officer at Therigy. Lily discusses challenges treating Hepatitis C patients and explains how a specialty patient management platform can improve outcomes. She introduces Therigy’s latest publication series: Specialty Pharmacy Standards of Care. Download the first volume in this series here: Specialty Pharmacy Standards of Care: Hepatitis C. Read on for Lily’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.          Powered by WPeMatico Continue reading Enhancing Care For and Management of Hepatitis C Patients

Drug Prices After the Midterms: Five Crucial Implications of Pharmacy Benefit Design

After Tuesday’s election, House minority leader Nancy Pelosi pointed to “reducing the cost of prescription drugs” as a legislative priority. But addressing patient affordability issues will require more than decrying “high drug prices.” Today, I highlight five implications of these benefit designs on patient affordability, out-of-pocket costs, and perceptions of prescriptions prices. My observations are based on Employer Pharmacy Benefits in 2018: More Tiers, Greater Coinsurance, and Lots of High-Deductible Plans, in which I summarized companies’ 2018 prescription drug coverage for their employees. As I explain below, many aspects of employers’ plans are unfriendly to patients with serious medical conditions … Continue reading Drug Prices After the Midterms: Five Crucial Implications of Pharmacy Benefit Design

Employer Pharmacy Benefits in 2018: More Tiers, Greater Coinsurance, and Lots of High-Deductible Plans

It’s time for a deep dive into the 2018 Kaiser Family Foundation Employer Health Benefits Survey, which you can read online for free. The survey provides valuable national benchmarking for employer-sponsored health coverage in 2018. If you’d rather not to wade through the entire report, please enjoy my highlights on prescription coverage below. I summarize employers’ 2018 pharmacy benefits by examining (1) cost sharing tier structures, (2) prevalence of copayment vs. coinsurance, and (3) average copayments and coinsurance rates, by formulary tier. I breakdown the 2018 results for plans with and without high deductibles. For 2018, employers continue to increase … Continue reading Employer Pharmacy Benefits in 2018: More Tiers, Greater Coinsurance, and Lots of High-Deductible Plans

CBI’s Specialty Therapies 2019

CBI’s Specialty Therapies 2019 January 24-25, 2019 | Las Vegas, NV www.cbinet.com/specialtytherapies Kick off 2019 in Las Vegas at Specialty Therapies 2019! Don’t miss the chance to come together with colleagues from across the industry to examine disruptions in specialty drug distribution and the impact on access, quality and cost. You can read all about it here. Visit www.cbinet.com/specialtytherapies for further details and to register. Drug Channels readers will save $400 off the standard rate when they use promo code BQH229 and register prior to November 30th.* With the advent of innovative service delivery models, alternative payment models and an … Continue reading CBI’s Specialty Therapies 2019

FDA’s $100 Million Real-World Evidence Project: Making It All It Can Be

Paul Glimcher In a sign of the increasing role real-world evidence (RWE) will have in healthcare research, FDA recently announced a $100 million proposal to build a modern system to gather RWE from about 10 million individuals. The good news is that this could transform clinical trials Powered by WPeMatico Continue reading FDA’s $100 Million Real-World Evidence Project: Making It All It Can Be

RMAT Designations: Lessons Learned on the Clinical Evidence Requirement

The 21st Century Cures Act (Cures Act), signed into law in December 2016, was designed to reduce regulatory obstacles for FDA approval of innovative medical therapies and accelerate the process of bringing innovative products to patients in need. Included in the Cures Act was a pathway to accele Powered by WPeMatico Continue reading RMAT Designations: Lessons Learned on the Clinical Evidence Requirement